Drug intelligence / Profile preview

anandamide

Development stage
Unknown
Modality
Small Molecules
Administration
Experimental (intravenous, Intraperitoneal In Animal Models)
01

Overview

Anandamide is an endogenous lipid mediator, classified as an endocannabinoid, structurally described as arachidonylethanolamide. It acts as an agonist of cannabinoid receptors, especially cannabinoid receptor 1 (CB1) and, to a lesser extent, cannabinoid receptor 2 (CB2), and can also interact with other molecular targets such as G protein–coupled receptor 55 (GPR55). Anandamide is synthesized in the brain and other animal tissues and participates in physiological processes including pain regulation, mood, appetite, memory, and modulation of the hypothalamic–pituitary–adrenal (HPA) axis. Unlike classic neurotransmitters, anandamide is produced on demand from membrane phospholipid precursors. After release and action, it is rapidly degraded by fatty acid amide hydrolase (FAAH). It is not an approved pharmaceutical, but is widely used as a research tool to study the endocannabinoid system[1][2][3][5][6][7][9][10].

Other names
arachidonylethanolamideN-arachidonylethanolaminearachidonyl ethanolamidearachidonic acid N-(hydroxyethyl)amide
02

Targets

GPR55 (G protein-coupled receptor 55)CNR2 (Cannabinoid receptor type 2)

Beyond the preview

Go deeper on anandamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anandamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call